Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2011 – December 31, 2011 Compiled by Lynn Day, RN BSN CCM CCRP.

Slides:

Advertisements

Similar presentations

Mammary ductal carcinoma

Advertisements

Evidence for adjuvant radiation therapy benefiting breast cancer patients with 1 to 3 positive lymph nodes treated with a modified radical mastectomy and.

Baptist Health System General Surgery Residency Program

Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.

Pimp Session: Breast By James Lee, MD.

Advances and Emerging Therapy for Lung Cancer

Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Breast Cancer in Pregnancy

Modified Megestrol The Clinical Trials by : Carolina R. Akib

Breast Reconstruction: Outcomes Analysis Michael J Bass, MD, JD Michael J Bass Plastic Surgery, PLLC.

Breast Cancer Tumor Board Chair Harold Burstein, MD, PhD Faculty Jennifer Bellon, MD Mehra Golshan, MD.

Oncology Assessment and Management of Patients With Cancer Breast Prepared by Dr. Iman Abdullah.

Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.

Sentinel Lymph Node Dissection (SND)

What is cancer? A cancer is a malignant tumor, which are cells that multiply out of control, destroying healthy tissues (Dictionary)

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

AJCC TNM Staging 7th Edition Breast Case #3

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.

Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.

Hot topics in breast radiotherapy Mark Beresford.

Ductal Carcinoma in situ

Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA

Maximally-Invasive Curriculum: A Model Curriculum for Osteopathic Surgical Residencies (ACOS) India Broyles, EdD University of New England College of Osteopathic.

Nurse Navigators and the Cancer Institute Yousuf A. Gaffar, MD Hematology / Medical Oncology The Cancer Institute University of Maryland St. Joseph Medical.

Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.

Ductal Carcinoma In Situ (DCIS)

Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.

Breast Carcinoma. Anatomy Epidemiology: 10% 17.1/10 28/10 46/ m world wide 6% develop cancer of the breast in their lifetime. 50,000 to 70,000.

Breast Cancer Methods for Early Detection. Breast Cancer What It Is Methods of Early Detection Risk Factors.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

NYU Medical Grand Rounds Clinical Vignette Daniel P. Eiras, MD, MPH PGY2 December 1, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

Care Plan Demo Dr Laura Esserman This work is licensed under a Creative Commons Attribution 3.0 Unported License. © 2007 Laura J Esserman.

Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2013 – December 31, 2013 Compiled by Uzma Nazim, M.D.

2014 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.

How are Auckland Surgeons Managing the Axilla? E Whineray Kelly, O Pellet, L Neave, J Harman, R Harman. Auckland Breast Cancer Study Group.

Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.

Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.

MBCG Project Primary Results MEDICALSURVEYS-17 RESEARCH GROUP IN COLLABORATION WITH THE EASO.

Recent and evolving trends in breast and colon cancer by Jeff Kolbasnik.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2014 – December 31, 2014 Compiled by L.Day, RN BSN CCM CCRP OCN 1.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2009 – December 31, 2009.

2015 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Breast Cancer Jeorge Kristoffer R. Duldulao, RN. Breast Cancer A rapid, unregulated growth of abnormal cells originating from the breast tissue.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP.

Extranodal Extension on Sentinel Lymph Node Dissection: Why Should We Treat It Differently? Audrey Choi MD, Matthew Surrusco MD, Samuel Rodriguez MD, Khaled.

Basis and Outcome of Axillary Dissection for Node Negative Axilla Gurpreet Singh Dept. Of Surgery P.G.I.M.E.R. These Power Point presentations are free.

SLNB Scenario Group Discussion Presented at: The Sentinel Lymph Node Biopsy Surgery Refresher Course October 29, 2010.

Breast Cancer 1. Leukemia & Lymphoma New diagnoses each year in the US: 112, 610 Adults 5,720 Children 43,340 died of leukemia or lymphoma in

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,

BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.

Presented at the NAACCR Annual Conference Quebec City June 22, 2010.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Harvard Medical School Date 06/01/2007.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

Advanced loco regional Regional breast cancer

Oncology Assessment and Management of Patients With Cancer Breast

The POSITIVE study A large international research effort coordinated by International Breast Cancer Study Group (IBCSG) worldwide ALLIANCE for Clinical.

BREAST CANCER ONCOLOGY NAVIGATION SERVICE

Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT

徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2

Presentation transcript:

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2011 – December 31, 2011 Compiled by Lynn Day, RN BSN CCM CCRP

Stage Distribution Total Number of Patients = 107 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun12 (22.22%) 22 (40.74%) 11 (20.37%) 4 (7.41%) 0 (0%) 5 (9.26%) 54 (100%) Jul - Dec8 (15.09%) 19 (35.85%) 10 (18.87%) 2 (3.77) 0 (0%) 14 (26.42%) 53 (100%) Jan-Dec20 (18.69%) 41 (38.32%) 21 (19.63%) 6 (5.61%) 0 (0%) 19 (17.76%) 107 (100%) Compiled by Lynn Day, RN BSN CCM CCRP

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Preoperative Core 11 (20.37%) 22 (40.74%) 10 (18.52%) 4 (7.41%) 0 (0%) 5 (9.26%) 52 (96.3%) Jul – Dec Preoperative Core 6 (11.32%) 19 (35.85%) 10 (18.87%) 2 (3.77%) 0 (0%) 13 (24.53%) 50 (94.34%) Jan-Dec Preoperative Core 17 (15.88%) 41 (38.32%) 20 (18.69%) 6 (5.61%) 0 (0%) 18 (16.82%) 102 (95.33%) Mode of Diagnosis Total Number of Patients = % of patients had diagnosis established on preoperative core needle biopsy Exceptions – discordant core biopsy Compiled by Lynn Day, RN BSN CCM CCRP

Tumor Board Discussion Total Number of Patients = 107 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Discussed 6/6 (50.0%) 13/22 (59.09%) 9/11 (81.82) 4/4 (100%) 0 (0%) 4/5 (80%) 36/54 (66.67%) Jul – Dec Discussed 4/8 (50.0%) 14/19 (73.68%) 9/10 (90.0%) 2/2 (100%) 0 (0%) 11/14 (78.57%) 40/53 (75.47%) Jan-Dec Discussed 10/20 (50.0%) 27/41 (65.85%) 18/21 (85.71) 6/6 (100%) 0 (0%) 15/19 (78.95%) 76/107 (71.03%) 71.03% of patients were discussed prospectively in the multidisciplinary tumor conference Compiled by Lynn Day, RN BSN CCM CCRP

Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun MDC seen 8/12 (66.67%) 20/22 (90.91%) 11/11 (100%) 3/4 (75%) 0 (0%) 1/5 (20%) 43/54 (79.63%) Jul – Dec MDC seen 5/8 (62.5%) 14/19 (73.68%) 7/10 (70.0%) 2/2 (100%) 0 (0%) 7/14 (50.0%) 35/53 (66.04%) Jan-Dec MDC seen 13/20 (65.0%) 34/41 (82.93% 18/21 (85.71%) 5/6 (83.33%) 0 (0%) 8/19 (42.11%) 78/107 (72.9%) Multidisciplinary Assessment (Surgical, Medical and Radiation Oncologist) Total Number of Patients = 107 Exceptions29/107 (27.1%) No radiation oncology evaluation (mast./ high-risk)16/29 (55.17%) No documentation in the chart 5/29 (17.24%) Patient non-compliance 5/29 (17.24%) Continuing chemotherapy 3/29 (10.34%) Compiled by Lynn Day, RN BSN CCM CCRP

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Assigned 10/12 (83.33%) 22/22 (100%) 11/11 (100%) 4/4 (100%) 0 (0%) 2/5 (40%) 49/54 (90.74%) Jul – Dec Assigned 7/8 (87.50%) 17/19 (89.47%) 9/10 (90.0%) 2/2 (100%) 0 (0%) 12/14 (85.71%) 47/53 (88.68%) Jan-Dec Assigned 17/20 (85.0%) 39/41 (95.12%) 20/21 (95.24%) 6/6 (100%) 0 (0%) 14/19 (73.68%) 96/107 (89.72%) Nurse Navigation Total Number of Patients = 107 Exceptions11/107 (10.28%) Lateral entry into the system11/11 (100%)* * modifications made to ensure assignment of a nurse navigator for every patient Compiled by Lynn Day, RN BSN CCM CCRP

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 1/12 (8.33%) 22/22 (100%) 9/11 (81.82%) 4/4 (100%) 0 (0%) 0/5 (0%) 36/54 (66.67%) Jul – Dec Yes 0/8 (0%) 18/19 (94.74%) 10/10 (100%) 2/2 (100%) 0 (0%) 0/14 (0%) 30/53 (56.6%) Jan-Dec Yes 1/20 (5%) 40/41 (97.56%) 19/21 (90.48%) 6/6 (100%) 1/2 (50.0%) 0/19 (0%) 66/107 (89.6%) CAP Compliance Total Number of Patients = 107 Exceptions41/107 (38.32%) Progesterone receptor not reported17/41 (41.5%) Complete response, no margins 8/41 (19.5%) Final surgery not done yet (neoadjuvant)14/41 (34.1%) Patient non-compliance, no follow up 2/41 (4.9%) Compiled by Lynn Day, RN BSN CCM CCRP

Axillary Staging Total Number of Patients = 107 Total Number of Patients with Invasive Cancer = 87 Number node positive patients on needle biopsy11/87 (12.6%) Number of patients eligible for SLNB76/87 (87.4%) – Number of patients with SLNB54/87 (62.1%) Exceptions12/87 (13.79%) Determined low risk (unlikely to change treatment plan)4/12 (33.3%) Final surgery not done yet 5/12 (41.7%) Patient non-compliance, no follow up2/12 (16.7%) Compiled by Lynn Day, RN BSN CCM CCRP

Axillary Dissection Total Number of Patients = 107 Total Number of Patients with Invasive Cancer = 87 Number of Patients with node positive disease 25/87 (28.7%) Number of patients eligible for ALND 25 – Number of patients with ALND 14/25 (56%) Exceptions11/25 (44%) Low risk for non-SLN mets. on MSKCC nomogram7/25 (28%) Final surgery not done yet 3/25 (12%) Patient refused completion ALND1/25 (4%) Compiled by Lynn Day, RN BSN CCM CCRP

Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 8/12 (66.67%) 19/22 (86.36%) 8/11 (72.73%) 1/4 (25.0%) 0 (0%) 0/5 (0%) 36/54 (66.67%) Jul – Dec Yes 6/8 (75.0%) 12/19 (63.16%) 3/10 (30.0%) 0/2 (0%) 0 (0%) 3/14 (21.43%) 24/53 (45.28%) Jan-Dec Yes 14/20 (70.0%) 31/41 (75.61%) 11/21 (52.38%) 1/6 (16.67%) 0 (0%) 3/19 (15.79%) 60/107 (56.07%) Breast Conservation Total Number of Patients = 107 Number of early stage patients (0, I and II) with breast conservation 56/82 (68.29%) Compiled by Lynn Day, RN BSN CCM CCRP

Post-lumpectomy Radiation Total Number of Patients = 107 Number of patients with lumpectomy60/107 (56.1%) Number of patients eligible for Radiation60 – Number of patients radiated50/60 (83.33%) Exceptions10/60 (16.7%) Low risk malignancy age group 75 – 93 years6/10 (60%) severe co morbidities Radiation pending3/10 (30%) Patient non-compliance 1/10 (10%) Number of patients radiated within 12 months48/50 (96%) Compiled by Lynn Day, RN BSN CCM CCRP

Post-Mastectomy Radiation Total Number of Patients = 107 Number of patients with mastectomy31/107 (29%) Number eligible for radiation (>T3 or >N2)5/31 (16.1%) – Number of patients radiated3/5 (60%) Exceptions2/5 (40%) - Radiation pending1/5 (20%) - Patient non-compliance 1/5 (20%) Number of patients radiated within 12 months5/5 (100%) Compiled by Lynn Day, RN BSN CCM CCRP

Systemic Chemotherapy - I Total Number of Patients = 107  ER negative patients with cancer10/107 (9.35%) Number eligible for chemotherapy(exclude DCIS)7/10 (70%) – Number treated with chemotherapy6/7 (85.7%) Exceptions1/7 (14.29%) Patient refused (1 stage I)1/1 (100%)  Number with chemotherapy within 4 months6/6 (100%) Exceptions0 (none) Patient non-compliance 0 (none) Compiled by Lynn Day, RN BSN CCM CCRP

Systemic Chemotherapy - II Total Number of Patients = 107  ER positive patients with cancer94/107 (87.9%) Number eligible for chemotherapy (exclude DCIS)77/94 (81.9%) Number treated with chemotherapy45/77 (58.4%)  Number with chemotherapy within 4 months43/45 (95.5%) Exceptions2/45 (4.4%) Prevented by patient comorbidities (stage III)1/2 (50%) Postop. wound complications (stage I)1/2 (50%) Compiled by Lynn Day, RN BSN CCM CCRP

Systemic Endocrine Therapy Total Number of Patients = 107  Number of ER positive patients94/107 (89.7%) Number treated with endocrine therapy69/94 (73.4%) Exceptions25/94 (26.6%) Determined risk > benefit 4/25 (16%) No documentation in the chart 1/25 (4%) Hormonal therapy pending 17/25 (68%) Patient sought treatment elsewhere 1/25 (4%) Patient non-compliance 2/25 (8%)  Number with endocrine therapy within 1 year69/69 (100%) Compiled by Lynn Day, RN BSN CCM CCRP

Rehabilitation Total Number of Patients = 107 Number enrolled in CPRP (PT/OT)24/107 (22.43%) Exceptions83/107 (77.6%) Services were available but structured program is pending definitive establishment, whereby every patient gets a baseline arm girth and shoulder range of motion documented; prospective data is maintained with a pre-designed schedule. Improvement over % Compiled by Lynn Day, RN BSN CCM CCRP

Genetic Counseling Total Number of Patients = 107 Number of patients with family history or < 45 years65/107 (60.75%) Number received genetic counseling20/65 (30.77%) – Number tested17/20 (85%) Positive 2/17 (11.76%) Negative15/17 (88.23%) – Number refused testing 3/20 (15%) Exceptions45/65 (69.23%) Did not meet NCCN criteria34/45 (75.5%) No documentation in the chart9/45 (20%) Compiled by Lynn Day, RN BSN CCM CCRP

Time Frame Trial / StudyEligible N (%) Participation N (%) Jan – Jun B-SMART18 (38.3%)15 (38.5%) SPOC40 (85.1%)36 (92.3%) ACOSOG Z10717 (14.9%)7 (17.9%) Total 47 (87%)39 (72.2%) Jul - Dec B-SMART13 (27.7%)10 (27%) SPOC37 (78.7%)34 (91.9%) ACOSOG Z Total 47 (88.68%)37 (69.81%) Trial Participation Total Number of Patients = 107 Total Number of patients enrolled in trials in /107 (87.85%) Increase of patients enrolled over the year /15 (526.6%) Compiled by Lynn Day, RN BSN CCM CCRP